Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2019-03 Issue:3 Volume:20 Page:339-351
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gnant Michael,Pfeiler Georg,Steger Günther G,Egle Daniel,Greil Richard,Fitzal Florian,Wette Viktor,Balic Marija,Haslbauer Ferdinand,Melbinger-Zeinitzer Elisabeth,Bjelic-Radisic Vesna,Jakesz Raimund,Marth Christian,Sevelda Paul,Mlineritsch Brigitte,Exner Ruth,Fesl Christian,Frantal Sophie,Singer Christian F

Publisher

Elsevier BV

Subject

Oncology

Reference40 articles.

1. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment;Gnant;Breast Care,2017

2. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial;Forbes;Lancet Oncol,2008

3. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials;Lancet,2015

4. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials;Lancet,2015

5. Fracture incidence after 3 years of aromatase inhibitor therapy;Bouvard;Ann Oncol,2014

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of denosumab in osteoporosis – an update on efficacy and drug safety;Expert Opinion on Drug Safety;2024-09-11

2. Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer;British Journal of Cancer;2024-09-09

3. Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells;Cell Death Discovery;2024-08-24

4. Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review;Frontiers in Oral Health;2024-08-01

5. The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence;Frontiers in Oncology;2024-08-01